Cancer Drug Resistance
All Journals
Search
Log In
Editor-in-Chief:
Godefridus J. Peters
Indexing:
ESCI
,
PMC
,
Scopus
,
CAS
,
CNKI
,
Dimensions
,
Lens
,
Embase
,
Journal Rank:
Impact Factor 2024: 5.2 - Q1 (ONCOLOGY); CiteScore 2024: 8.3 - Q1 [Pharmacology(medical)]
Median time to first editorial decision:
9 days
Journal Flyer
Hot Keywords
Resistance
Drug delivery
Nanomedicine
Tumor microenvironment
Immune checkpoint inhibitors
Target therapy
Immunotherapy
Radiotherapy
Ferroptosis
PARP inhibitors
MYC
ABC transporters
Autophagy
Metabolism
Mechanisms
Precision medicine
Extracellular vesicles
Stem cell
Biomarker
Ovarian cancer
Renal cell carcinoma
Prostate cancer
Breast cancer
Colorectal cancer
Myeloid leukemia
Non-small cell lung cancer
Pancreatic cancer
Head and neck cancer
Squamous cell carcinoma
Mitochondria
Home
About
About the Journal
Aims and Scope
Editorial Policies
Editorial Board
Early‑Career Editorial Board
News
Journal History
Partners
Advertise
Contact Us
Publish with us
For Authors
Author Instructions
Article Processing Charges
Editorial Process
Manuscript Templates
Submit a Manuscript
For Reviewers
Peer Review Guidelines
Articles
All Articles
Editor’s Choice
Articles with Video Abstracts
Video Abstract Guidelines
Articles Ebooks
Special Topics
All Special Topics
Ongoing Special Topics
Completed Special Topics
Closed Special Topic
Special Topic Ebooks
Special Topic Guidelines
Special Collections
Volumes
Pre-onlines
Features
Webinars
Academic Talks
Interviews
Home
Articles
Special Topics
Volumes
Webinars
Videos
Menu
Cancer Drug Resistance
Search
Submit
Editor-in-Chief:
Godefridus J. Peters
Journal Rank:
Impact Factor 2024: 5.2 - Q1 (ONCOLOGY); CiteScore 2024: 8.3 - Q1 [Pharmacology(medical)]
Median time to first editorial decision:
9 days
Home
Articles
Special Topics
Volumes
Webinars
Videos
Menu
Home
Volumes
Volume
Acquisition of drug resistance in endothelial cells by tumor-derived extracellular vesicles and cancer progression
Targeting T regulatory (T<sub>reg</sub>) cells in immunotherapy-resistant cancers
Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxel
Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer
Reactive oxygen species and its role in pathogenesis and resistance to therapy in acute myeloid leukemia
Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors
Leveraging genomics, transcriptomics and epigenomics to understand chemoimmunotherapy resistance in chronic lymphocytic leukemia
Regulation of Nrf2/Keap1 signaling pathway in cancer drug resistance by galectin-1: cellular and molecular implications
Circular RNA circNCOA3 promotes tumor progression and anti-PD-1 resistance in colorectal cancer
Overcoming immuno-resistance by rescheduling anti-VEGF/cytotoxics/anti-PD-1 combination in lung cancer model
Dysregulation of calcium homeostasis in cancer and its role in chemoresistance
Mechanisms underlying reversed TRAIL sensitivity in acquired bortezomib-resistant non-small cell lung cancer cells
The therapeutic potential of circular RNA in triple-negative breast cancer
HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs
Emerging role of MYB transcription factors in cancer drug resistance
Isocucurbitacin B inhibits glioma growth through PI3K/AKT pathways and increases glioma sensitivity to TMZ by inhibiting hsa-mir-1286a
Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers
Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them
Chemosensitizing effect of pentoxifylline in sensitive and multidrug-resistant non-small cell lung cancer cells
ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies
Validation of single nucleotide polymorphisms potentially related to R-CHOP resistance in diffuse large B-cell lymphoma patients
Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer
The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer
Recent advanced lipid-based nanomedicines for overcoming cancer resistance
Inhibition of glutaminolysis alone and in combination with HDAC inhibitor has anti-myeloma therapeutic effects
Unraveling the complexity of drug resistance mechanisms to SINE, T cell-engaging therapies and CELMoDs in multiple myeloma: a comprehensive review
Impact of genetic variants in the solute carrier (<i>SLC</i>) genes encoding drug uptake transporters on the response to anticancer chemotherapy
Targeting NETosis: nature’s alarm system in cancer progression
The uniqueness of ABCB5 as a full transporter ABCB5FL and a half-transporter-like ABCB5β
The role of circRNAs and miRNAs in drug resistance and targeted therapy responses in breast cancer
Research progress on the role and mechanism of circular RNA in drug resistance of head and neck squamous cell carcinoma
Cancer-associated fibroblast cell surface markers as potential biomarkers or therapeutic targets in lung cancer
Current applications of tumor local ablation (TLA) combined with immune checkpoint inhibitors in breast cancer treatment
Non-coding RNA and drug resistance in head and neck cancer
Intercellular transfer of multidrug resistance mediated by extracellular vesicles
Screening of photosensitizers-ATP binding cassette (ABC) transporter interactions <i>in vitro</i>
Competing endogenous RNAs (ceRNAs) and drug resistance to cancer therapy
Emerging roles of small extracellular vesicles in metabolic reprogramming and drug resistance in cancers
Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies
The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer models
NFE2L2 and ferroptosis resistance in cancer therapy
Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma
The role and clinical applications of exosomes in cancer drug resistance
Fra-1 affects chemotherapy sensitivity by inhibiting ferroptosis in gastric cancer cells
Reprogrammed lipid metabolism in advanced resistant cancers: an upcoming therapeutic opportunity
HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond
Mechanism of ferroptosis resistance in cancer cells
Breast cancer cell resistance to hormonal and targeted therapeutics is correlated with the inactivation of the NR6A1 axis
The emerging role of GLP-1 receptor agonists in treating or preventing cancer
Overcoming drug resistance through extracellular vesicle-based drug delivery system in cancer treatment
CIRCUS: CIRCUlating tumour cells in soft tissue Sarcoma - a short report
Role of the TME in immune checkpoint blockade resistance of non-small cell lung cancer
Ovarian tumor microenvironment contributes to tumor progression and chemoresistance
Mitochondrial genome variability and metabolic alterations reveal new biomarkers of resistance in testicular germ cell tumors
Mechanisms of immunotherapy resistance in small cell lung cancer
Actions for 0 selected articles
Download PDFs >
Cancer Drug Resistance
ISSN 2578-532X (Online)
[email protected]
Navigation
Contact Us
Sitemap
Follow Us
LinkedIn
Twitter
WeChat
Navigation
Contact Us
Sitemap
Committee on Publication Ethics
https://members.publicationethics.org/members/cancer-drug-resistance
Portico
All published articles will preserved here permanently:
https://www.portico.org/publishers/oae/
Committee on Publication Ethics
https://members.publicationethics.org/members/cancer-drug-resistance
Portico
All published articles will preserved here permanently:
https://www.portico.org/publishers/oae/